IMPACT OF DRUG-ELUTING STENT PLACEMENT COMPARED WITH BARE METAL STENT IN FEMOROPOPLITEAL DISEASE  by Kamioka, Norihiko et al.
Vascular Medicine
A2043
JACC April 1, 2014
Volume 63, Issue 12
impAct oF drug-eluting stent plAcement compAred with bAre metAl stent in 
FemoropopliteAl diseAse
Moderated Poster Contributions
Hall C
Monday, March 31, 2014, 10:00 a.m.-10:15 a.m.
Session Title: Platelets, Stents and Genes in Peripheral Artery Disease
Abstract Category: 31. Vascular Medicine: Endovascular Therapy
Presentation Number: 1282M-369B
Authors: Norihiko Kamioka, Yoshimitsu Soga, Yusuke Tomoi, Yohei Kobayashi, Kokura Memorial Hospital, Kitakyushu, Japan
background: The efficacy of drug-eluting stent (DES) implantation for the femoropopliteal (FP) disease in the real world is not yet clarified 
compared with bare metal nitinol stent (BMS).
methods: Between January 2004 and April 2013, 1150 consecutive patients who had received their first endovascular therapy for FP disease were 
identified. Of them, 377 cases (464 limbs) were analyzed in this study; 98limbs (21.1%) were implanted DES (Zilver PTX, Cook, Bloomington, IN), 
and 366 limbs (78.9%) were treated with BMS (S.M.A.R.T., Cordis J&J, Miami, FL). The primary outcome was defined as primary patency, and the 
secondary outcome as secondary patency, assisted-primary patency and major adverse limb events (MALE; included of any repeat revascularization 
or major amputation).
results: The mean reference vessel diameter was 5.1±1.0 mm and the mean lesion length was 152.4±93.4 mm. There was no significant 
difference in primary patency between DES group and BMS group (65.8% vs 72.5% at 1year, P=.25), nor was there a significant difference with 
secondary patency, assisted-primary patency, and MALE (P=.41, .07, and .32, respectively). The independent predictors of primary patency were 
female gender, diabetes, history of coronary artery disease, administration of thienopyridine, and absence of cilostazol.
conclusions: In our study, the impact of DES for FP stenting was not proved on primary patency, secondary patency, assisted-primary patency and 
MALE.
